Pharminent

Theravance COPD drug clears safety study, setting up NDA

Theravance Biopharma and Mylan are still on course to file for approval of their nebulized chronic obstructive pulmonary disease (COPD) therapy in the fourth quarter after posting 12-month safety data. The trial suggests revefenacin has a tolerable safety profile comparable to that of Boehringer Ingelheim’s bronchodilator Spiriva. http://www.fiercebiotech.com/biotech/theravance-copd-drug-clears-safety-study-setting-up-nda

Filed under: COPD